Short Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Declines By 17.9%

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totalling 12,730,000 shares, a decline of 17.9% from the June 30th total of 15,510,000 shares. Based on an average daily trading volume, of 6,250,000 shares, the short-interest ratio is currently 2.0 days.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. StockNews.com started coverage on Sangamo Therapeutics in a research note on Sunday. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.67.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System boosted its holdings in Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 23,650 shares during the period. Mackenzie Financial Corp lifted its holdings in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 31,003 shares during the period. Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 34,960 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics in the 1st quarter worth $331,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Sangamo Therapeutics by 14.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 129,811 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Down 23.6 %

Shares of NASDAQ SGMO traded down $0.22 during trading hours on Tuesday, hitting $0.70. 21,898,694 shares of the company traded hands, compared to its average volume of 5,671,591. The stock has a market capitalization of $145.26 million, a price-to-earnings ratio of -0.44 and a beta of 1.24. The company’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.61. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The business had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter in the previous year, the firm earned $0.12 EPS. Equities analysts anticipate that Sangamo Therapeutics will post -0.55 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.